NEW PROSTATE CANCER INFOLINK: Is more better when it comes to the number of samples taken in a prostate biopsy? Not according to new research. READ MORE>
Archive for the ‘Biopsy’ Category
Posted in Biopsy, tagged Biopsy, cancer research, catherise, catheter, catheterisation, Erectile function, impaired voiding, periprostatic nerve block, prostablog, prostate, prostate biopsy, prostate blog, PROSTATE CANCER, Saturation (20-core) prostate biopsy, Urination, URO TODAY, urology, voiding function on September 12, 2010 | Leave a Comment »
URO TODAY: Men having a biopsy for prostate cancer need to be warned that it will temporarily affect urination and may also have an impact on erectile function, a German study says. READ MORE>
Prostate biopsy causes impaired voiding (of the bladder).
Saturation (20-core) prostate biopsy and periprostatic nerve block seem to have a lasting impact on voiding function.
Erectile function is transiently affected by prostate biopsy regardless of periprostatic nerve block and the number of cores.
Patients who undergo prostate biopsy must be informed about these side effects.
Posted in Biopsy, MRI scans, PROSTATE CANCER, PROSTATE RESEARCH, tagged Biopsy, cancer research, catheter, electromagnetic needle tracking, endorectal coil MRI, improving biopsy quality control, MRI scan, needle biopsy, pre-procedure MRI, pre-procedure TRUS, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer screening, prostate under-sampling, transrectal ultrasonography (TRUS)-guided prostate biopsies, URO TODAY on July 24, 2010 | Leave a Comment »
URO TODAY: Knowing exactly where in the prostate a biopsy sample has come from is a problem for those diagnosing the disease, but scientists may have found a way to improve that by combining MRI scans with needle biopsy. READ MORE>
It is feasible to document the location of transrectal ultrasonography (TRUS)-guided prostate biopsies on pre-procedure MRI by fusing the pre-procedure TRUS to an endorectal coil MRI using electromagnetic needle tracking.
This procedure may be useful in documenting the location of prior biopsies, improving quality control and thereby avoiding under-sampling of the prostate, as well as directing subsequent biopsies to regions of the prostate not previously sampled.
Posted in Biopsy, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, SCREENING and DIAGNOSIS, tagged 5-Alpha reductase inhibitors, Biopsy, cancer research, catheter, Dutasteride, finasteride, fluctuating PSA levels, medical checkups, negative biopsy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer screening, prostate-specific antigen, PSA, PSA test, URO TODAY on June 12, 2010 | Leave a Comment »
Proportion of positive biopsy samples may be indicator of later success of hormone therapy for prostate cancer
Posted in Biopsy, PROSTATE CANCER, PROSTATE RESEARCH, tagged Biopsy, cancer research, catheter, Hormone therapy, positive core samples, prognosis of prostate cancer, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, URO TODAY on November 1, 2009 | Leave a Comment »
URO TODAY: The number of positive core samples in a biopsy for prostate cancer appears to be related to how successful hormone therapy will be later. READ MORE>
Our study of 403 patients with an overall mean follow-up of five years supports the concept of a significant association between the proportion of positive biopsy cores and the prognosis of prostate cancer treated by hormonal therapy.
‘Screening algorithm’ shown to accurately predict whether repeat biopsies for prostate cancer are needed
Posted in Biopsy, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Screening debate, tagged Biopsy, cancer research, Dutch medical scientists, individualized screening algorithm, medical checkups, pre-biopsy information, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer screening, prostate-specific antigen, PSA, repeated biopsies, subsequent screening visit, suspected prostate cancer, too late, unnecessary biopsies on October 8, 2009 | Leave a Comment »
URO TODAY: Dutch medical scientists have worked out a way to use various medical information – including PSA level – to accurately calculate whether a man needs repeated biopsies for suspected prostate cancer. READ MORE>
An individualized screening algorithm using other available pre-biopsy information in addition to PSA level can result in a considerable reduction of unnecessary biopsies. Very few important prostate cancer cases – for which diagnosis at a subsequent screening visit might be too late for treatment with curative intent – would be missed.